newsfilter
← Latest News
Business Wire·

DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

Independent Data Safety Monitoring Board to Conduct a Pre-Specified Interim Analysis to Assess Need for Sample Size Re-Estimation Interim Analysis Results Expected in Q1 2027 DiaMedica Therapeutics Inc.